The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2024 | The recent expanded approval of cilta-cel into earlier lines of myeloma therapy
Roberto Mina, MD, University of Turin, Turin, Italy, shares his thoughts on the recent expanded approval of ciltacabtagene autoleucel (cilta-cel) into earlier lines of treatment for multiple myeloma. This approval was based on the CARTITUDE-4 trial (NCT04181827) that showed improved survival outcomes and quality of life (QoL) as compared to standard of care (SoC) regimens. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
